Short answer
Sionna Therapeutics, Inc. (SION) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Quarterly results and business highlights for period ended September 30, 2026.
Sionna Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Quarterly results and business highlights for period ended September 30, 2026
- Investor-relevant financial details contained in furnished Exhibit 99.1 press release
- Filing signals a routine quarterly update, with no results figures in the 8-K text itself
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 net loss $32.4M, versus $20.3M, with nine-month loss reaching $89.1M
- Cash, equivalents and marketable securities $249.8M, expected to fund operations into the second half of 2029
- SION-451 plus SION-2222 Phase 2 proof-of-concept trial targeted for Q1 2027, following favorable Phase 1 safety and PK results
- SION-719 add-on program discontinued after missing its key endpoint, despite post hoc sweat chloride reduction up to 8.6 mmol/L
- Workforce reduced approximately 46%, concentrating resources on the lead combination and extending cash runway
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sionna Therapeutics, Inc. 8-K filings
Get the next SION 8-K as it lands
Follow SION for push alerts, or ask the research agent what this filing means.